{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T22:54:44Z","timestamp":1769381684792,"version":"3.49.0"},"reference-count":68,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2009,5,29]],"date-time":"2009-05-29T00:00:00Z","timestamp":1243555200000},"content-version":"vor","delay-in-days":759,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Review"],"published-print":{"date-parts":[[2007,5]]},"abstract":"<jats:p>In this Harm Reduction Digest Sheridan, Butler, Wilkins and Russell address the emergent phenomenon of so\u2010called \u2018legal party pills\u2019 which have become a significant drug issue in New Zealand and elsewhere. Although banned in a number of countries, they are currently legally available in New Zealand where they are marketed as \u2018safe' alternatives\u2019 to \u2018illicit\u2019 drugs often used in the dance scene such as MDMA and amphetamines. The authors describe the availability and use of these substances in New Zealand, summarize what is known about their effects, and speculate on harm reduction interventions and mechanisms of control and their possible sequelae. The paper provides a timely account of an emerging drug issue of relevance to harm reduction internationally.<\/jats:p>","DOI":"10.1080\/09595230701255791","type":"journal-article","created":{"date-parts":[[2007,5,24]],"date-time":"2007-05-24T02:12:19Z","timestamp":1179972739000},"page":"335-343","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Legal piperazine\u2010containing party pills\u2010a new trend in substance misuse"],"prefix":"10.1111","volume":"26","author":[{"given":"JANIE","family":"SHERIDAN","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"RACHAEL","family":"BUTLER","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"CHRIS","family":"WILKINS","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"BRUCE","family":"RUSSELL","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,5,29]]},"reference":[{"key":"e_1_2_1_2_2","first-page":"1","article-title":"Recent population trends in amphetamine use in New Zealand: comparison of findings from national household drug surveying in 1998, 2001 and 2003","volume":"119","author":"Wilkins C.","year":"2006","journal-title":"N Z Med J"},{"key":"e_1_2_1_3_2","first-page":"383","article-title":"Ecstasy use in New Zealand: findings from the 1998 and 2001 National Drug Surveys","volume":"116","author":"Wilkins C.","year":"2003","journal-title":"N Z Med J"},{"key":"e_1_2_1_4_2","unstructured":"New Zealand Herald.Restraints on party pills delayed. New Zealand Herald 2 April 2005.http:www.nzherald.co.nz\/search\/story.cfm?storyid=4CE0F228\u201039DE\u201011DA\u20108E1B\u2010A5B353C55561 accessed 29 January2007."},{"key":"e_1_2_1_5_2","unstructured":"TVNZ News.High dosage party pills sold in Christchurch 25 January 2006.http:tvnz.co.nzviewpage653425accessed 19 January2007."},{"key":"e_1_2_1_6_2","unstructured":"ArmstrongS.Legal highs: the new \u2018social tonics\u2019? New Statesman 2007;135(4815).http:www.newstatesman.com200610230025accessed19 January 2007."},{"key":"e_1_2_1_7_2","unstructured":"PerrottA.High Gear. Canvas 2 April2005 10\u201312."},{"key":"e_1_2_1_8_2","volume-title":"Legal party pill use in New Zealand: prevalence of use, availability, health harms and \u2018gateway effects\u2019 of benzylpi\u2010perazine (BZP) and triflourophenylmethylpiperazine (TFMPP)","author":"Wilkins C.","year":"2006"},{"key":"e_1_2_1_9_2","volume-title":"The socio\u2010economic impact of amphetamine type stimulants in New Zealand: final report","author":"Wilkins C.","year":"2004"},{"key":"e_1_2_1_10_2","first-page":"9","volume-title":"SHORE\/Whariki, editor","author":"Wilkins C.","year":"2005"},{"key":"e_1_2_1_11_2","first-page":"8","volume-title":"SHORE\/Whariki, editor","author":"Wilkins C.","year":"2005"},{"key":"e_1_2_1_12_2","first-page":"8","volume-title":"SHORE\/Whariki, editor","author":"Wilkins C.","year":"2005"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00558280"},{"key":"e_1_2_1_14_2","first-page":"201","article-title":"Comparison of serotonin agonistic and antagonistic activities of a new antidepressant agent Trelibet (EGYT\u2010475) and its metabolite EGYT\u20102760 on isolated rat fundus","volume":"78","author":"Malomvolgyi B.","year":"1991","journal-title":"Acta Physiol Hung."},{"key":"e_1_2_1_15_2","first-page":"107","article-title":"Pharmacokinetic aspects of the mode of action of EGYT\u2010475, a new antidepressant agent","volume":"39","author":"Magyar K.","year":"1987","journal-title":"Pol J Pharmacol Pharm"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2004.07.014"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300585"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-7158.1987.tb06249.x"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00558281"},{"key":"e_1_2_1_20_2","volume-title":"Pihkal: a chemical love story","author":"Shulgin A.","year":"1991"},{"key":"e_1_2_1_21_2","volume-title":"Erowid","year":"2004"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00168661"},{"key":"e_1_2_1_23_2","first-page":"1122","article-title":"m\u2010chlorophenylpi\u2010perazine and m\u2010trifluoromethylphenylpiperazine are partial agonists at cloned 5\u2010HT2A receptors expressed in fibro\u2010blasts","volume":"27","author":"Grotewiel M.","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_24_2","first-page":"552","article-title":"Relative efficacies of piperazines at the phosphoinositide hydrolysis\u2010 linked serotonergic (5\u2010HT\u20102 and 5\u2010HT\u20101c) receptors","volume":"242","author":"Conn P.","year":"1987","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-3057(88)90310-3"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-3057(92)90403-3"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2003.08.029"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1570-0232(01)00619-5"},{"key":"e_1_2_1_29_2","first-page":"1","article-title":"Toxic effects of BZP\u2010based herbal party pills in humans: a prospective study in Christchurch, New Zealand","volume":"118","author":"Gee P.","year":"2006","journal-title":"N Z Med J"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-3057(99)00253-1"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(96)00291-0"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291701003828"},{"key":"e_1_2_1_33_2","first-page":"301","article-title":"The need for speed: an update on methamphetamine addiction","volume":"31","author":"Barr A.","year":"2006","journal-title":"J Psychiatry Neurosci"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1124\/pr.55.3.3"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1080\/00223989809599162"},{"key":"e_1_2_1_36_2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1300\/J069v21n01_02","article-title":"Will the methamphetamine problem go away","volume":"21","author":"Rawson RA","year":"2002","journal-title":"J Addict Dis"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.158.3.383"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1002\/hup.351"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1665.2004.02137.x"},{"key":"e_1_2_1_40_2","first-page":"1","article-title":"Nephrotoxicity of BZP\u2010based herbal party pills: a New Zealand case report","volume":"119","author":"Alansari M.","year":"2006","journal-title":"NZ Med J"},{"key":"e_1_2_1_41_2","unstructured":"ClaridgeA.Pill casualties down 50%. The Press (Christch\u2010urch) 27 September2006."},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-6723.2006.00826.x"},{"key":"e_1_2_1_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06108-6"},{"key":"e_1_2_1_44_2","doi-asserted-by":"publisher","DOI":"10.1136\/oem.57.10.649"},{"key":"e_1_2_1_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.smrv.2005.11.001"},{"key":"e_1_2_1_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1054-139X(02)00506-2"},{"key":"e_1_2_1_47_2","unstructured":"Candor TrustParty pills and driving \u2010 the wider issues. In:NewsSI editorScoop Independent News. 18 January 2007http:www.scoop.co.nzstoriesPO0701S00075.htmaccessed 29 January 2007."},{"key":"e_1_2_1_48_2","unstructured":"MarshallJ.Party pill study aborted over \u2018severe adverse events\u2019. New Zealand Herald 21 January2007.http:www.nzherald.co.nz\/search\/story.cfm?storyid=0008CFE2\u2010B3B2\u201015B2\u2010AEE683027AF10192 accessed 29 January 2007."},{"key":"e_1_2_1_49_2","doi-asserted-by":"publisher","DOI":"10.1080\/09595230412331289482"},{"key":"e_1_2_1_50_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-003-1714-5"},{"key":"e_1_2_1_51_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002130050714"},{"key":"e_1_2_1_52_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.1992.tb02003.x"},{"key":"e_1_2_1_53_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.1997.tb02951.x"},{"key":"e_1_2_1_54_2","doi-asserted-by":"publisher","DOI":"10.1080\/09595239800186991"},{"key":"e_1_2_1_55_2","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/sj.npp.1395197","article-title":"Psychological and cardiovascular efffects and short\u2010term sequelae of MDMA (\u2018ecstasy\u2019) in MDMA\u2010naive health volunteers","volume":"19","author":"Vollenweider F.","year":"1998","journal-title":"Neuropsychopharmacology"},{"key":"e_1_2_1_56_2","doi-asserted-by":"publisher","DOI":"10.1080\/09687630600577550"},{"key":"e_1_2_1_57_2","doi-asserted-by":"publisher","DOI":"10.1080\/16066350412331323074"},{"key":"e_1_2_1_58_2","volume-title":"National Drug Policy: A National Drug Policy for New Zealand 1998\u20132003","author":"Ministry of Health","year":"1998"},{"key":"e_1_2_1_59_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2005.01134.x"},{"key":"e_1_2_1_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/0379-0738(87)90074-0"},{"key":"e_1_2_1_61_2","unstructured":"Social Tonics Association of New Zealand.Code of Practice for the Manufacture Labelling Distribution and Marketing of Social Tonics in New Zealand. 2005.http:www.stanz.org.nzCode20of20Practice20\u20102020Post20Consultation20Final20Draft.pdfaccessed22 January 2007."},{"key":"e_1_2_1_62_2","unstructured":"Expert Advisory Committee on Drugs.The Expert Advisory Committee on Drugs (EACD): advice to the Minister on: benzylpiperazine (BZP): EACD Wellington 2004."},{"key":"e_1_2_1_63_2","volume-title":"Further EACD advice on Benzylpiperazine (BZP) and related substances","author":"Expert Advisory Committee on Drugs.","year":"2006"},{"key":"e_1_2_1_64_2","first-page":"12794","article-title":"Department of Justice. Schedules of controlled substances; placement of 2,5\u2010dimethoxy\u20104\u2010(n)\u2010propylthiophenethylamine and N\u2010benzyl\u2010piperazine into Schedule I of the Controlled Substances Act. Final rule","volume":"69","author":"Drug Enforcement Administration.","year":"2004","journal-title":"Federal Register"},{"key":"e_1_2_1_65_2","first-page":"1","article-title":"N\u2010substituted piperazines abused by humans mimic the molecular mechanism of 3,4\u2010methylenedioxy\u2010methamphetamine (MDMA, or \u2018Ecstasy\u2019)","volume":"28","author":"Baumann M.","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"e_1_2_1_66_2","volume-title":"Clubbers snap up new legal high","author":"McCandless D.","year":"2005"},{"key":"e_1_2_1_67_2","unstructured":"News Item.ACMD refers benzylpiperazine (BZP) issue to Europe: P.E.P Pills 2006;http:www.pep\u2010pills.co.uknewsnews\u2010itemsacmd\u2010ferers\u2010bzp\u2010issue\u2010to\u2010europeaccessed 22 January 2007."},{"key":"e_1_2_1_68_2","doi-asserted-by":"publisher","DOI":"10.1080\/16066350500053703"},{"key":"e_1_2_1_69_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2003.11.009"}],"container-title":["Drug and Alcohol Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1080%2F09595230701255791","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1080%2F09595230701255791","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1080\/09595230701255791","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T18:40:24Z","timestamp":1699987224000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1080\/09595230701255791"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5]]},"references-count":68,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,5]]}},"alternative-id":["10.1080\/09595230701255791"],"URL":"https:\/\/doi.org\/10.1080\/09595230701255791","archive":["Portico"],"relation":{},"ISSN":["0959-5236","1465-3362"],"issn-type":[{"value":"0959-5236","type":"print"},{"value":"1465-3362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,5]]},"assertion":[{"value":"2009-05-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}